EZH2 and neoplasm: The Deazaneplanocin A (DZNep), an EZH2 inhibitor, was tested along with the small-molecule compound AC1Q3QWB (AQB) in vitro, as well as in orthotopic breast cancer and GBM patient-derived xenograft (PDX) models, and was demonstrated to significantly reduce tumor growth [69].